UiPath For Coding Agents Prompts Fresh Look At UiPath (PATH) Valuation And Undervaluation Debate

Why UiPath’s new coding agent platform matters for PATH stock watchers

UiPath (PATH) has drawn fresh attention after launching UiPath for Coding Agents, an industry first integration that makes popular AI coding agents deployable, orchestrated, and governed inside enterprise automation workflows.

For investors, this product launch sits alongside UiPath’s broader agentic AI initiatives, including recent Automation Suite updates for regulated industries and government agencies. It also offers additional context for evaluating PATH following a period of weaker share price performance.

See our latest analysis for UiPath.

Even with these AI launches, PATH’s recent share price momentum has been weak. The stock is at US$9.47 after a 1 day share price return that declined 5.39% and a 1 year total shareholder return that declined 28.31%, suggesting sentiment has been fading rather than building.

If you are looking beyond PATH for other AI automation ideas, this is a useful moment to see which robotics and automation peers are drawing interest through the 30 robotics and automation stocks.

After a long stretch of weak returns and fresh buzz around its agentic AI launches, the key question is whether UiPath at US$9.47 reflects too much pessimism or if the market is already pricing in future growth.

Most Popular Narrative: 56% Undervalued

According to the most followed narrative for UiPath, a fair value of $21.54 sits well above the last close at $9.47, pointing to a wide valuation gap that some investors are watching closely.

UiPath’s platform helps businesses automate routine digital tasks such as processing invoices, entering data and connecting systems that do not normally work together. What makes it special is that it can work across almost any software, even legacy programs, using its AI computer vision. The system can see what is on a screen and take action, just like a person would. These challenging integration processes can create strong moat for them as one of the early leader in the space.

Read the complete narrative.

Curious how that moat story turns into a $21+ fair value? The narrative leans heavily on steady top line expansion, improving margins, and a premium earnings multiple. The specific mix of growth and profitability assumptions driving that number is where things get interesting.

Result: Fair Value of $21.54 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this story can break if big platform rivals win automation budgets faster than expected, or if new AI features fail to convert into meaningful adoption.

Find out about the key risks to this UiPath narrative.

Next Steps

If this mix of optimism and caution leaves you undecided, it may be worth moving quickly to check the details and form your own stance using the 4 key rewards.

Looking for more investment ideas?

If PATH leaves you unsure, do not just sit on the sidelines. Use focused stock lists to spot fresh opportunities that better fit your goals and risk comfort.

• Target potential mispricings by scanning companies highlighted as 46 high quality undervalued stocks and see which ones might deserve a closer look.
• Prioritize resilience by focusing on businesses in the 68 resilient stocks with low risk scores and see which profiles line up with your need for steadier compounding.
• Get ahead of the crowd by reviewing the screener containing 23 high quality undiscovered gems and see which lesser known stocks could deserve a spot on your watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com